Shunho Shares Report Strong Growth in 2024 Half-Year Results

Business by 2FIRSTS.ai
Aug.19.2024
Shunho Shares Report Strong Growth in 2024 Half-Year Results
Shanghai Shunho released its 2024 semi-annual report, with a 29.98% revenue increase, focusing on e-cigarette and industrial hemp projects.

On August 17th, Shanghai Shunho New Material Technology Co., Ltd. (Stock abbreviation: Shunho shares, stock code: 002565) released its semi-annual report for the year 2024.

Shunho Shares Report Strong Growth in 2024 Half-Year Results


A report shows that the company achieved operating revenue of approximately 706 million yuan during the reporting period, an increase of 29.98% year-on-year. However, the company's business in the field of new tobacco products has decreased, with operating revenue of 2,700,885.54 yuan, accounting for 0.38% of the total operating revenue of the company, a decrease of 30.65% from the same period last year. This may be due to factors such as changes in market environment, policy adjustments, or company strategic realignments. The operating revenue from e-cigarette projects was 4.66 million yuan, while the industrial hemp project had operating revenue of 83,500 yuan.

Shunho Shares Report Strong Growth in 2024 Half-Year Results


According to reports, Shunho's subsidiary Greencore has obtained the Tobacco Monopoly Production Enterprise License for e-cigarette processing companies in the new tobacco field. Its invested company, Meizhonglian, has obtained the Tobacco Monopoly Production Enterprise License for e-cigarette product manufacturing companies. Meanwhile, Shunho's subsidiary Yilong has obtained the Tobacco Monopoly Production Enterprise License for e-cigarette brand holding companies for domestic sales.


The company stated that its subsidiary Shunho Yilong's "Yilong" brand e-cigarette has been launched in some retail stores in Beijing, Shenzhen, and Shanghai areas, and will continue to promote the listing of "Yilong" products in multiple locations in the future.


In addition, the company's wholly-owned subsidiary Yunnan Lvxin has obtained the "Yunnan Province Industrial Hemp Processing License," which means the company is qualified to process industrial hemp in Qujing City, Yunnan Province. To seize the rapidly growing opportunities in the overseas industrial hemp market, Shunho Corporation has established a subsidiary, Kinneloa Holdings Inc., in the United States. With legal qualifications to carry out industrial hemp processing and manufacturing related business in the US, as well as sales in other legal countries and regions worldwide. Kinneloa Holdings Inc.'s wholly-owned subsidiary, E1011 Labs, has launched ELON second-generation HNB devices and Stelo heating rod products.


Another wholly-owned subsidiary of the company, Vitaldiol Pharmaceutical, has launched the Vitaldiol – R Series (Recover, Relief, Rest) products and Essential elixirs for the US market. These products contain ingredients such as CBD, NMN (Nicotinamide Mononucleotide), turmeric, melatonin, and others, emphasizing a "minimalist ingredients" and "natural health" concept.


The report mentioned that the global e-cigarette market is expected to continue growing, and the company stated that they will increase research and development investment to further expand the new tobacco industry both domestically and overseas.


We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

JUUL2 Sued Within a Week of FDA Authorization as AJ Marketing Alleges Infringement of Programmable Vape Patent
JUUL2 Sued Within a Week of FDA Authorization as AJ Marketing Alleges Infringement of Programmable Vape Patent
Less than a week after JUUL2 received U.S. FDA marketing authorization on August 28, 2026, JUUL Labs was sued for patent infringement in federal court in Delaware. AJ Marketing LLC filed the complaint on September 3, alleging that both JUUL 1 and JUUL2 infringe U.S. Patent No. 8,851,068 B2. The patent covers aspects of programmable electronic vaporization devices, including controls over dose delivery, usage frequency and operating parameters. The plaintiff is seeking reasonable royalties and ongoing royalties tied to the remaining life of the patent. JUUL has not yet publicly responded to the case.
Sep.10
On-Site Report | CTP Details PMTA Backlog, 180-Day Review Goal and sPMTA Process
On-Site Report | CTP Details PMTA Backlog, 180-Day Review Goal and sPMTA Process
FDA’s Center for Tobacco Products detailed new PMTA review data and process changes at the 2026 FDLI conference. Pending PMTAs fell from about 450,000 at the start of 2025 to 135,000 by September 2026. CTP also discussed its 180-day review goal, current sPMTA pilot, alternate-supplier planning, more than 50,300 pending SE reports, and lessons from the nicotine pouch pilot already being applied to ENDS review.
Regulations
Oct.07
NAS 2026 | FDA CTP Director Says PMTA Pathway Is “Predicated on Tobacco Harm Reduction”
NAS 2026 | FDA CTP Director Says PMTA Pathway Is “Predicated on Tobacco Harm Reduction”
At the 2026 New Approaches Summit in New York, FDA Center for Tobacco Products Director Bret Koplow said the PMTA pathway is “predicated on tobacco harm reduction.” He outlined four CTP priorities: youth prevention, helping adults quit or switch to lower-risk products, improving relative-risk communication, and reducing unauthorized products. Koplow also addressed flavored e-cigarettes, public risk perceptions, industry credibility and efforts to make PMTA reviews more efficient and predictable.
Sep.26
Gallery | InterTabac 2026 Opens as VAPORESSO, SKE, GREENTANK, GEEK BAR and Other Brands Take the Floor
Gallery | InterTabac 2026 Opens as VAPORESSO, SKE, GREENTANK, GEEK BAR and Other Brands Take the Floor
InterTabac 2026 opened in Dortmund, Germany, on September 15 alongside NUBIZ and InterSupply. According to the latest figures released by the organizer, the three trade shows bring together around 750 exhibitors from 64 countries. On site, 2Firsts observed vaping and related brands including VAPORESSO, DOJO, SKE, GREENTANK, GEEK BAR, HQD and ELUX.
Special Report
Sep.15
Charlie’s Bets on Age-Gating and 678 PMTA Assets as U.S. Vape Enforcement Landscape Shifts
Charlie’s Bets on Age-Gating and 678 PMTA Assets as U.S. Vape Enforcement Landscape Shifts
Charlie’s Holdings said in its latest shareholder letter that it is moving to commercialize PACHA products and monetize its PMTA assets as the FDA changes enforcement priorities for unauthorized ENDS products. Thirty PACHA SKUs were previously tentatively identified for a proposed public list of products that the FDA generally does not intend to prioritize for enforcement. Charlie’s is also preparing test-market sales of age-gated flavored disposables and says it currently holds 678 PMTA-related product assets while seeking additional strategic transactions and partnerships.
Sep.11
FDA Appoints Former Tobacco Enforcement Deputy Jessica Zeller as Director as Agency Weighs PMTA Framework Changes
FDA Appoints Former Tobacco Enforcement Deputy Jessica Zeller as Director as Agency Weighs PMTA Framework Changes
The U.S. Food and Drug Administration (FDA) has named Jessica Zeller director of the Center for Tobacco Products' (CTP) Office of Compliance and Enforcement (OCE), effective November 1, 2026. Zeller, the office's inaugural deputy director, returns from medical device manufacturer Edwards Lifesciences with more than 20 years of regulatory and legal experience. The appointment follows CTP leadership changes and adjustments to tobacco regulation. Bret Koplow became permanent CTP director in September; the FDA revised enforcement priorities for unauthorized e-cigarettes and nicotine pouches in May and announced faster PMTA review procedures. On September 28, the agency said it would evaluate changes to the existing PMTA regulatory framework, including potential rulemaking to replace it.
FDA
Oct.20 by 2Firsts Perspectives